Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 639 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research July 13, 2020 What could DeepMind ‘solving’ the protein folding problem mean for cancer... December 23, 2020 Workout Wednesdays – Chest Exercises Part 1 June 10, 2020 FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer February 20, 2023 Load more HOT NEWS New on NCI’s Websites for December 2021 Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera
